Calithera Biosciences Provides Overview of 2020 Corporate Milestones and Financial Guidance | CALA Message Board Posts

Calithera Biosciences, Inc.

  CALA website

CALA   /  Message Board  /  Read Message

 

 






Keyword
Subject
Between
and
Rec'd By
Authored By
Minimum Recs
  
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board
Msg  2751 of 2762  at  1/18/2020 6:48:48 PM  by

JoeFlow


 In response to msg 2750 by  wilderguide
view thread

Re: Calithera Biosciences Provides Overview of 2020 Corporate Milestones and Financial Guidance

 agreed - 445 patients is really big for P2 trial and should be enough to file for approval while starting a P3 trial.  I'm hoping ORR is through the roof relative to cabo mono therapy...  PFS and OS should also get a big boost and would help get a quick FDA decision if ORR and PFS are significantly higher.
I could see EXEL buying into CALA but hope it's not an outright purchase... maybe 20%-30% stake... developing a combo pill of cabo+CB839 may be a way to cabo extend patent life...  speculating here...


     e-mail to a friend      printer-friendly     add to library      
| More
Recs: 5     Views: 183
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board

Replies
Msg # Subject Author Recs Date Posted
2752 Re: Calithera Biosciences Provides Overview of 2020 Corporate Milestones and Financial Guidance wilderguide 3 1/18/2020 8:36:49 PM






About Us  •  Contact Us  •  Follow Us on Twitter  •  Members Directory  •  Help Center  •  Advertise
Not a member yet? What are you waiting for? Create Account
Want to contribute? Support InvestorVillage by donating
© 2003-2019 Investorvillage.com. All rights reserved. User Agreement
   
Financial Market Data provided by
.


Loading...